NIH R01 · 2024
Mechanistic Study of PEG-asparaginase-Induced Liver Injury
Project Summary PEGylated asparaginase (PEG-ASNase) is one of the main drugs used for the treatment of pediatric acute lymphoblastic leukemia (ALL). Although PEG-ASNase is safe and effective to treat pediatric ALL, its use in adults is limited due to dose-limiting liver injury that negatively impacts therapeutic efficacy. Therefore, strategies that can mitigate the risk of PEG-ASNase liver injury are urgently needed. Our preliminary data show that (1) our murine model of PEG-ASNase liver injury recapitulates clinical features, (2) PEG-ASNase activates ATGL, leading to white adipose tissue (WAT) lipolysis and hepatic lipid peroxidation and apoptosis; (3) PEG-ASNase sensitizes hepatocytes to…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.